1. a b c d e Moriguchi et al., Supplementary Fig. S1
Latency on retention trials (s) a b c d e
Discrimination index (%)
Latency on first trials (s)
Total arm entries
Alternations (%)
Moriguchi et al., Supplementary Fig. S1

2. a b c Moriguchi et al., Supplementary Fig. S2 fEPSP slope (% of cont)
fEPSP amplitude (mV)
Moriguchi et al., Supplementary Fig. S2

3. a b Moriguchi et al., Supplementary Fig. S3
Phosphorylation (% of cont)
Moriguchi et al., Supplementary Fig. S3

4. a b
Moriguchi et al., Supplementary Fig. S4

5. a b Moriguchi et al., Supplementary Fig. S5 K+ current (pA) Cont Mem
Pin
50 pA
Moriguchi et al., Supplementary Fig. S5

6. a b Moriguchi et al., Supplementary Fig. S6 Kir6.1 NeuN Merged Kir6.2
MAP2
Merged
Kir6.2
MAP2
Merged
Kir6.1
GFAP
Merged
Kir6.2
GFAP
Merged
Moriguchi et al., Supplementary Fig. S6

7. a b c Moriguchi et al., Supplementary Fig. S7
Protein levels (% of cont)
Protein levels (% of cont)
Moriguchi et al., Supplementary Fig. S7

8. a b c d e f g h i Moriguchi et al., Supplementary Fig. S8
Latency on retention trials (s) a b c
Discrimination index (%) d
Latency on first trials (s) e
Total arm entries
Alternations (%) f g h i
Protein levels (% of cont)
fEPSP slope (% of cont)
fEPSP slope (% of cont)
Moriguchi et al., Supplementary Fig. S8

9. a b c Moriguchi et al., Supplementary Fig. S9
Phosphorylation (% of cont)
Protein levels (% of cont)
Moriguchi et al., Supplementary Fig. S9

10. a b c d e f g Moriguchi et al., Supplementary Fig. S10
Latency on retention trials (s) a b c d e
Discrimination index (%)
Latency on first trials (s)
Total arm entries
Alternations (%) f g
fEPSP slope (% of cont)
fEPSP slope (% of cont)
Moriguchi et al., Supplementary Fig. S10

11. a b c d Moriguchi et al., Supplementary Fig. S11
fEPSP slope (% of cont)
fEPSP slope (% of cont) c d
Phosphorylation (% of cont)
Moriguchi et al., Supplementary Fig. S11

12. a b Moriguchi et al., Supplementary Fig. S12
Phosphorylation (% of cont)
Moriguchi et al., Supplementary Fig. S12

13. a b c d Moriguchi et al., Supplementary Fig. S13 Immobility time (s)
Number of BrdU-positive cells/ area
Moriguchi et al., Supplementary Fig. S13

14. a b c d Moriguchi et al., Supplementary Fig. S14 Immobility time (s)
Number of BrdU-positive cells/ area
Moriguchi et al., Supplementary Fig. S14

15. Moriguchi et al., Supplementary Fig. 15
Blood glucose levels (mg/dl)
Moriguchi et al., Supplementary Fig. 15